Side-by-side research comparison of Ipamorelin and Sermorelin across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 45 Ipamorelin studies and 89 Sermorelin studies.
| Ipamorelin | Sermorelin | |
|---|---|---|
| Drug class | ghrh secretagogue, ghrelin mimetic | ghrh analog |
| Studies in corpus | 45 | 89 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 | other · 26 rct · 15 cohort · 1 in vitro · 19 preclinical animal · 22 review · 2 |
| Studies with explicit sample size | 3 | 2 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Ipamorelin and Sermorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1801 Ipamorelin batches across 637 manufacturers, 99.52% avg purity.
We tested 909 Sermorelin batches across 373 manufacturers, 99.21% avg purity.
We hold deeper lab coverage on Ipamorelin (1801 batches tested). Ipamorelin edges ahead on average measured purity (99.52% vs 99.21%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on Ipamorelin or Sermorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.